ストックスクリーナーアプリを入手
0.9702
4.88%
-0.0498
アフターアワーズ：
.97
-0.0002
-0.02%
Enlivex Therapeutics Ltd (ENLV) 最新ニュース
Enlivex Therapeutics Releases 2024 Financial Statements - TipRanks
Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Friday - Defense World
HC Wainwright Has Negative Estimate for ENLV FY2025 Earnings - Defense World
Enlivex Therapeutics (NASDAQ:ENLV) Given New $7.00 Price Target at HC Wainwright - Defense World
Enlivex stock price target raised to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa
Enlivex stock price target raised to $7 at H.C. Wainwright - Investing.com India
Enlivex Secures Chinese Patent Allowance for Osteoarthritis Treatment - TipRanks
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis - The Manila Times
Enlivex Therapeutics Secures Patent Allowance in China for Allocetra™ as Treatment for Osteoarthritis - Nasdaq
Breakthrough: Enlivex's Arthritis Drug Cuts Pain by 47%, Secures Major China Patent Win - StockTitan
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update - Defense World
IOBT To Report Melanoma Trial Data In Q3, NPCE Eyes 15-20% Revenue Growth For 2025, DXR On Watch - RTTNews
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis - The Manila Times
Enlivex Reports Promising Interim Results in Osteoarthritis Trial - TipRanks
Enlivex Therapeutics Announces Investor Webinar To Discuss Positive Interim Data From Phase I/Ii Allocetra(TM) Trial In Knee Osteoarthritis - Marketscreener.com
Enlivex Therapeutics Ltd. Hosts Investor Webinar to Discuss Positive Interim Data from Allocetra™ Osteoarthritis Trial - Nasdaq
Can Enlivex's Allocetra Transform Osteoarthritis Treatment? 47% Pain Reduction Reported - StockTitan
Enlivex Therapeutics (NASDAQ:ENLV) Given Buy Rating at D. Boral Capital - Defense World
Enlivex Announces Positive Interim Data From Early Stage Trial For Osteoarthritis Treatment - Nasdaq
Enlivex Reports Promising Interim Results in Knee Osteoarthritis Trial - TipRanks
Enlivex Announces Positive Interim DataStatistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis - The Manila Times
Enlivex Therapeutics Reports Positive Interim Results in Phase I/II Trial of Allocetra™ for Knee Osteoarthritis - Nasdaq
Can Enlivex's Osteoarthritis Treatment Disrupt a Multi-Billion Dollar Market? 6-Month Data Impresses - StockTitan
We're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Rate - Simply Wall St
Enlivex Advances Immunotherapy with Japanese Patent for Osteoarthritis Treatment - PUNE.NEWS
Enlivex Therapeutics (NASDAQ:ENLV) Hails Positive Trial Results for Allocetra Treatment of Knee Osteoarthritis - Markets Insider
Enlivex Therapeutics Starts Phase II Allocetra Trail to Treat Knee Osteoarthritis - Markets Insider
Enlivex Wins Key Patent in Japan for Osteoarthritis Treatment - Markets Insider
Enlivex Therapeutics Completes Initial Dosing in Phase I Psoriatic Arthritis Trial - Markets Insider
Enlivex Issues Urgent Statement on Fraudulent News Dissemination - The Manila Times
Enlivex Therapeutics Denies False Report of Trading Suspension and Reaffirms Business Operations - Nasdaq
Enlivex Takes Legal Action Against Market Manipulation as Stock Trading Continues Uninterrupted - Stock Titan
CollPlant Biotechnologies Provides a Corporate Update - Quantisnow
Tryptamine Therapeutics Appoints New Auditor Amid Global Expansion - TipRanks
RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis - Yahoo Finance
Enlivex Therapeutics’ (ENLV) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Up 1.9% – Time to Buy? - Defense World
Sepsis Market Forecasted to Surge in Coming Years, 2024-2034 - openPR
Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis - ACCESS Newswire
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3 - ACCESS Newswire
Head-To-Head Analysis: Bright Minds Biosciences (NASDAQ:DRUG) versus Enlivex Therapeutics (NASDAQ:ENLV) - Defense World
Enlivex CEO to Showcase Breakthrough Allocetra Cell Therapy on Bloomberg TV Special Feature - StockTitan
Hoth’s phase IIa derma data in cancer patients propels its stock - BioWorld Online
Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Up 6% – Still a Buy? - Defense World
Enlivex gains Israeli regulatory approval to commence TMJ osteoarthritis trial - Yahoo Finance
Enlivex Receives Regulatory Authorization for the Initiation of A Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - Marketscreener.com
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - The Manila Times
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis - The Manila Times
Trump's crypto advocacy steers businesses away from traditional treasury assets - Yahoo Canada Finance
Enlivex's Allocetra Trial Shows 50% Pain Reduction in Knee Osteoarthritis Study - StockTitan
Enlivex Therapeutics Faces Financial Challenges Amid Losses - TipRanks
Enlivex to Showcase Promising Allocetra™ Cell Therapy Data in Exclusive Investor Webinar | ENLV Stock News - StockTitan
Enlivex Therapeutics to Invest in Bitcoin as Part of Cash Management Strategy - Binance
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):